Original article

N-terminal Pro-brain Natriuretic Peptide and High-sensitivity Troponin in the Evaluation of Acute Chest Pain of Uncertain Etiology. A PITAGORAS Substudy

Juan Sanchis,a,⁎ Alfredo Bardaji,b Xavier Bosch,c Pablo Loma-Osorio,d Francisco Marín,e Pedro L. Sánchez,f Francisco Calvo,g Pablo Avanzas,h Carolina Hernández,i Silvia Serrano,j Arturo Carratalá,k and José A. Barrabésl

⁎ Servicio de Cardiología, Hospital Clínico Universitario, INCLIVA, Universitat de València, Valencia, Spain
a Servicio de Cardiología, Hospital Universitari Joan XXIII, ISPV, Universitat Rovira i Virgili, Tarragona, Spain
b Servicio de Cardiología, Hospital Clinic, Universitat de Barcelona, Barcelona, Spain
c Servicio de Cardiología, Hospital Josep Trueta, Girona, Spain
d Servicio de Cardiología, Hospital Universitari Virgen de la Arrixaca, Universidad de Murcia, Murcia, Spain
e Servicio de Cardiología, Hospital Gregorio Marañón, Madrid, Spain
f Servicio de Cardiología, Hospital de Medico, Vigo, Pontevedra, Spain
g Servicio de Cardiología, Hospital General de Asturias, Oviedo, Asturias, Spain
h Servicio de Cardiología, Hospital Clínico Universitario, Valladolid, Spain
i Servicio de Cardiología, Hospital Germans Trias i Pujol, Badalona, Barcelona, Spain
j Servicio de Bioquímica Clínica, Hospital Clínico Universitario, INCLIVA, Valencia, Spain
k Servicio de Cardiología, Hospital Universitari Vall d’Hebron, Institut de Recerca (VHIR), Universitat Autònoma de Barcelona, Barcelona, Spain

Article history:
Received 24 September 2012
Accepted 8 November 2012
Available online 29 January 2013

Keywords:
Acute coronary syndrome
Natriuretic peptides
Troponin

A B S T R A C T

Introduction and objectives: High-sensitivity troponin assays have improved the diagnosis of acute coronary syndrome in patients presenting with chest pain and normal troponin levels as measured by conventional assays. Our aim was to investigate whether N-terminal pro-brain natriuretic peptide provides additional information to troponin determination in these patients.

Methods: A total of 398 patients, included in the PITAGORAS study, presenting to the emergency department with chest pain and normal troponin levels as measured by conventional assay in 2 serial samples (on arrival and 6 h to 8 h later) were studied. The samples were also analyzed in a central laboratory for high-sensitivity troponin T (both samples) and for N-terminal pro-brain natriuretic peptide (second sample). The endpoints were diagnosis of acute coronary syndrome and the composite endpoint of in-hospital revascularization or a 30-day cardiac event.

Results: Acute coronary syndrome was adjudicated to 79 patients (20%) and the composite endpoint to 59 (15%). When the N-terminal pro-brain natriuretic peptide quartile increased, the diagnosis of acute coronary syndrome also increased (12%, 16%, 23% and 29%; P=0.01), as did the risk of the composite endpoint (6%, 13%, 16% and 24%; P=0.004). N-terminal pro-brain natriuretic peptide elevation (>125 ng/L) was associated with both endpoints (relative risk=2.0; 95% confidence interval, 1.2–3.3; P=0.02; relative risk=2.4; 95% confidence interval, 1.4–4.2; P=0.004). However, in the multivariable models adjusted by clinical and electrocardiographic data, a predictive value was found for high-sensitivity T troponin but not for N-terminal pro-brain natriuretic peptide.

Conclusions: In low-risk patients with chest pain of uncertain etiology evaluated using high-sensitivity T troponin, N-terminal pro-brain natriuretic peptide does not contribute additional predictive value to diagnosis or the prediction of short-term outcomes.

© 2012 Sociedad Española de Cardiología. Published by Elsevier España, S.L. All rights reserved.

Fracción aminoterminal del propéptido natriurético cerebral y troponina ultrasensible en el dolor torácico agudo de origen incierto. Un subestudio del estudio PITAGORAS

R E S U M E N

Introducción y objetivos: La troponina ultrasensible ha mejorado el diagnóstico del síndrome coronario agudo en los pacientes que se presentan con dolor torácico y troponina convencional normal. Nuestro objetivo es analizar si la fracción aminoterminal del propéptido natriurético cerebral aporta información adicional.

Métodos: Se estudió a 398 pacientes, incluidos en el estudio PITAGORAS, que acudieron a urgencias por dolor torácico con troponina convencional normal en dos muestras seriadas (a la llegada y a las 6-8 h). Se midió de forma centralizada la troponina T ultrasensible en las dos muestras y la fracción aminoterminal

Palabras clave:
Síndrome coronario agudo
Péptidos natriuréticos
Troponina

SEE RELATED ARTICLE:
* Corresponding author: Servicio de Cardiología, Hospital Clínico Universitario, Avda. Blasco Ibáñez 17, 46010 Valencia, Spain.
E-mail address: sanchis_juafor@gva.es (J. Sanchis).
del propéptido natriurético cerebral en la segunda. Los objetivos fueron diagnóstico de síndrome coronario agudo y evento compuesto de revascularización o evento cardíaco a los 30 días.

**Resultados:** Se diagnosticó síndrome coronario agudo a 79 pacientes (20%), y 59 (15%) presentaron el evento compuesto. A superior cuartil de la fracción aminoterminal del propéptido natriurético cerebral se incrementan las frecuencias de diagnóstico de síndrome coronario agudo (el 12, el 16, el 23 y el 29%; p = 0,01) y del evento compuesto (el 6, el 13, el 16 y el 24%; p = 0,004). La elevación de la fracción aminoterminal del propéptido natriurético cerebral (> 125 ng/l) se asoció con ambos objetivos (riesgo relativo = 2,0; intervalo de confianza del 95%, 1,2-3,3; p = 0,02; riesgo relativo = 2,4; intervalo de confianza del 95%, 1,4-4,2; p = 0,004). Sin embargo, en los modelos multivariantes ajustados por datos clínicos y el electrocardiograma, la troponina T ultrasensible mostró valor predictivo, pero no la fracción aminoterminal del propéptido natriurético cerebral.

**Conclusiones:** En el dolor torácico de origen incierto y bajo riesgo evaluado mediante troponina T ultrasensible, la fracción aminoterminal del propéptido natriurético cerebral carece de valor predictivo adicional para el diagnóstico o el pronóstico a corto plazo.

**Abreviaturas**

ACS: acute coronary syndrome  
ECG: electrocardiogram  
Hs-TnT: high-sensitivity troponin T  
PITAGORAS: troPonina ulTrAsensible en pacientes atendidos en urGencias por dOlOr toRácico en hospitales esPañoles  
(in English: High-Sensitivity Troponin in Patients With Chest Pain Presenting To Spanish Emergency Departments)  
NT-proBNP: N-terminal pro-brain natriuretic peptide

**INTRODUCTION**

In patients attending the emergency service for chest pain who have normal troponin levels, decision making requires careful evaluation of the medical history, electrocardiogram (ECG), exercise test, imaging stress test or coronary computed tomographic angiography. In a considerable proportion of patients with normal troponin levels, chest pain is due to acute coronary syndrome (ACS). In this complex scenario, a biomarker that would be readily available 24 h per day/7 days per week and that could add to the information provided by troponin would be extremely useful.

Among the various biomarkers studied, those that have most consistently been shown to have prognostic value in the entire spectrum of ACS, including the subgroup of patients with normal troponin levels, are natriuretic peptides. Nevertheless, most studies of these peptides were performed before the introduction of high-sensitivity troponin assays and consequently the utility of these peptides as a possible addition to risk stratification using high-sensitivity troponins is unknown.

The PITAGORAS (troPonina ulTrAsensible en pacientes atendidos en urGencias por dOlOr toRácico en hospitales esPañoles [in English: High-Sensitivity Troponin in Patients With Chest Pain Presenting To Spanish Emergency Departments]) is a multicenter study performed in Spain that evaluated the Elecsys® high-sensitivity troponin T (hs-TnT) assay (Roche Diagnostics; Basel, Switzerland) in patients with chest pain and normal troponin levels measured by conventional assays. The principal results of this study indicated that the main instruments for the diagnosis of ACS in these patients are the clinical history and ECG, although undetectable hs-TnT levels had a high negative predictive value that could be clinically useful.

The aim of the present study was to analyze whether the N-terminal pro-brain natriuretic peptide (NT-proBNP) provides additional information to hs-TnT determination in establishing the diagnosis and prognosis of these patients.

**MATERIAL AND METHODS**

PITAGORAS is a Spanish prospective multicenter study designed by the Section for Ischemic Heart Disease and Coronary Care Units of the Spanish Society of Cardiology. The main objective of this study was to evaluate the role of hs-TnT in the diagnosis of ACS in patients presenting to the emergency department with chest pain and who have normal troponin levels as measured by the reagents used in the routine clinical practice of each hospital. The participating hospitals are listed in the Appendix.

The methodology of the PITAGORAS study and its principal results concerning hs-TnT have previously been described. Briefly, the study included patients presenting to the emergency department for chest pains of uncertain etiology with onset in the previous 24 h and who were suspected of having ACS in the opinion of the duty cardiologist. The exclusion criteria were as follows: a) persistent ST-segment elevation on the emergency ECG; b) elevated troponin levels in 1 of 2 serial determinations (at arrival at the emergency department and 6 h to 8 h later) as determined by the method routinely used in each hospital; c) a prior diagnosis of myocardial ischemia established by a finding of significant coronary stenosis in a previous coronary angiogram or prior documented myocardial infarction; d) left bundle branch block or other ventricular repolarization alterations that could make the result of an exercise test impossible to interpret, or physical inability to perform exercise; e) known structural heart disease other than myocardial ischemia, and f) significant concomitant heart failure, or bradycardia (≥55 bpm), or tachycardia (≥110 bpm).

The total population included in the PITAGORAS study consisted of 446 patients. Due to logistic difficulties in the referring hospitals or in the central laboratory where the hs-TnT and NT-proBNP determinations were performed, data on NT-proBNP were unavailable in 48 patients due to the lack of to blood sample. Consequently, the present subanalysis was performed in a population of 398 patients.

**Determination of High-sensitivity Troponin T and N-terminal Pro-brain Natriuretic Peptide**

Two blood samples were obtained for troponin determination with the method routinely used in each hospital. These samples were also used to determine hs-TnT in a single central laboratory. In the second sample (taken 6 h to 8 h after arrival at the emergency department) NT-proBNP was also obtained. To do this, all the blood samples were centrifuged after extraction and were then frozen at –80 °C and transferred to the central laboratory for biomarker measurement. Both hs-TnT and NT-proBNP determinations were performed using their respective assays in an automatic immunochemical analyzer Cobas e601 (Roche Diagnostics; Basel,
Switzerland). The limit of detection for hs-TnT is 3 ng/L and the 99th percentile of the reference limit of a healthy population is 14 ng/L. The upper reference limit recommended by the manufacturer for NT-proBNP is 125 ng/L.

**Diagnostic Protocol**

Clinical variables were gathered in all patients (Table 1). The approach adopted was guided by the findings of the ECG performed in the emergency department. Patients with an ECG suggestive of ischemia (ST-segment depression >0.5 mm or negative T wave >2 mm in 2 adjacent leads) were admitted for coronary angiography. The remaining patients were assigned to a noninvasive test for ischemia (preferentially to a conventional exercise test or stress cardiac imaging according to the routine practice in each hospital). If the results of the test were positive, coronary angiography was indicated; if the results were negative, the patient was discharged, and if the results were inconclusive, coronary angiography or an alternative test for ischemia was performed (although coronary angiography was recommended by the protocol).

**Endpoints**

The primary endpoint was diagnosis of ACS as the cause of chest pain, with consensus on this diagnosis being reached by 3 cardiologists who were blind to the results of hs-TnT testing. The criterion for the diagnosis of ACS was angiographic evidence of significant coronary stenosis or, if angiography had not been performed, a positive result of a noninvasive test for ischemia, or the occurrence of a 30-day cardiac event. To ensure the robustness of the diagnosis, the protocol recommended the performance of angiography after an ECG result suggesting ischemia or after a positive or inconclusive result of a noninvasive test for ischemia. Likewise, the study’s exclusion criteria included evidence of coronary stenosis in a prior coronary angiogram, because, in these patients, a current coronary angiogram would always lead to a diagnosis of ACS.

The secondary endpoint was the composite endpoint of revascularization or a 30-day cardiac event, including death or acute myocardial infarction (a new episode of chest pain with elevated troponin levels). An acute myocardial infarction was also deemed to have occurred when the creatine-kinase-MB mass increased to >3 times the upper limit of normality after coronary angioplasty, or to >5 times this limit after coronary surgery, evaluated at 8 h and 24 h after the revascularization procedure.

**Statistical Analysis**

Continuous variables are presented as the mean (standard deviation), and qualitative variables as absolute values and percentages. Hs-TnT was used in such a way that the results of the PITAGORAS study showed their best discriminative ability: the highest of the 2 hs-TnT determinations was taken and the population was divided into 3 categories: <3 ng/L (undetectable levels), ≥3 ng/L but <14 ng/L (levels were detectable but below the 99th percentile), and ≥14 ng/L (levels above the 99th percentile). 17

Because the distribution of NT-proBNP followed a non-normal pattern, values for this variable are presented as median and interquartile ranges. In the univariable analysis to compare values among groups with and without the primary and secondary endpoints, a nonparametric test was used (Mann-Whitney test). The population was distributed among the NT-proBNP quartiles and the groups were compared by using the chi-square test. Likewise, the population was dichotomized by taking the cut-off point for the upper limit of normality recommended by the manufacturer (≥125 ng/L) and estimating relative risks (RR) with their 95% confidence intervals (95%CI). The sensitivity, specificity, positive predictive value, negative predictive value, and 95%CI

<table>
<thead>
<tr>
<th>Table 1</th>
<th>Characteristics of the Total Population and the Subgroups With and Without a Final Diagnosis of Acute Coronary Syndrome</th>
<th></th>
<th>Without ACS (n=319)</th>
<th>With ACS (n=79)</th>
<th>P</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age, years</td>
<td>All (n=398)</td>
<td>60±12</td>
<td>59±12</td>
<td>64±12</td>
<td>.002</td>
</tr>
<tr>
<td>Males</td>
<td>235 (59)</td>
<td>180 (56)</td>
<td>55 (70)</td>
<td>.04</td>
<td></td>
</tr>
<tr>
<td>Exercise-related chest pain</td>
<td>124 (31)</td>
<td>78 (25)</td>
<td>46 (58)</td>
<td>.0001</td>
<td></td>
</tr>
<tr>
<td>≥2 episodes in the last 24 h</td>
<td>132 (33)</td>
<td>93 (29)</td>
<td>39 (49)</td>
<td>.001</td>
<td></td>
</tr>
<tr>
<td>Smoking</td>
<td>104 (26)</td>
<td>82 (26)</td>
<td>22 (28)</td>
<td>.8</td>
<td></td>
</tr>
<tr>
<td>Hypertension</td>
<td>214 (54)</td>
<td>170 (53)</td>
<td>44 (56)</td>
<td>.7</td>
<td></td>
</tr>
<tr>
<td>Hypercholesterolemia</td>
<td>184 (46)</td>
<td>142 (45)</td>
<td>42 (53)</td>
<td>.2</td>
<td></td>
</tr>
<tr>
<td>Diabetes</td>
<td>79 (20)</td>
<td>51 (16)</td>
<td>28 (35)</td>
<td>.0001</td>
<td></td>
</tr>
<tr>
<td>Family history</td>
<td>59 (15)</td>
<td>42 (13)</td>
<td>17 (22)</td>
<td>.08</td>
<td></td>
</tr>
<tr>
<td>Peripheral artery disease</td>
<td>5 (1.3)</td>
<td>2 (0.6)</td>
<td>3 (3.8)</td>
<td>.06</td>
<td></td>
</tr>
<tr>
<td>History of stroke</td>
<td>10 (2.5)</td>
<td>9 (2.8)</td>
<td>1 (1.3)</td>
<td>.4</td>
<td></td>
</tr>
<tr>
<td>Prior antiplatelet therapy</td>
<td>82 (21)</td>
<td>56 (18)</td>
<td>26 (33)</td>
<td>.005</td>
<td></td>
</tr>
<tr>
<td>Prior statin therapy</td>
<td>115 (29)</td>
<td>81 (25)</td>
<td>34 (43)</td>
<td>.003</td>
<td></td>
</tr>
<tr>
<td>Prior beta-blocker therapy</td>
<td>44 (11)</td>
<td>35 (11)</td>
<td>9 (11)</td>
<td>.8</td>
<td></td>
</tr>
<tr>
<td>Systolic blood pressure on admission, mmHg</td>
<td>144±24</td>
<td>143±24</td>
<td>147±22</td>
<td>.2</td>
<td></td>
</tr>
<tr>
<td>Diastolic blood pressure on admission, mmHg</td>
<td>80±13</td>
<td>80±13</td>
<td>79±12</td>
<td>.8</td>
<td></td>
</tr>
<tr>
<td>Heart rate on admission, bpm</td>
<td>76±15</td>
<td>76±15</td>
<td>77±14</td>
<td>.5</td>
<td></td>
</tr>
<tr>
<td>Ischemia on ECG (ST-segment depression ST&lt;0.5 mm/negative T wave&gt;2 mm)</td>
<td>55 (14)</td>
<td>28 (9)</td>
<td>27 (34)</td>
<td>.0001</td>
<td></td>
</tr>
<tr>
<td>Baseline creatinine, mg/dL</td>
<td>0.9±0.2</td>
<td>0.9±0.2</td>
<td>0.9±0.2</td>
<td>.6</td>
<td></td>
</tr>
</tbody>
</table>

ACS, acute coronary syndrome; ECG, electrocardiogram.
Values are expressed as no. (%) or mean±standard deviation.
were calculated for NT-proBNP $>$ 125 ng/L and for hs-TnT $>$ 14 ng/L (the cut-point corresponding to the 99th percentile of the reference population). For the multivariable analysis, a binary logistic regression was used (backward conditional method with an exit criteria; $P$=0.1) in which the clinical and ECG variables related to the endpoints in the univariable analysis, hs-TnT and NT-proBNP, were introduced. Odd ratio (OR), 95%CI and the C statistic were calculated. The statistical analysis was performed using the SPSS 18.0 statistical package (SPSS Inc.; Chicago, Illinois, United States).

RESULTS

Characteristics of the Population

Table 1 shows the characteristics of the study population. Table 2 shows the differences with the population in the PITAGORAS study who were excluded (n=48) due to lack of a blood sample for NT-proBNP determination. There were no differences between the 2 groups, except that the frequency of smoking and a family history of myocardial ischemia was higher in patients included in the NT-proBNP substudy.

The median interval from the onset of chest pain to extraction of the first blood sample was 4 h (interquartile range, 3 h to 6 h). The median NT-proBNP value was 66 ng/L (range, 5 ng/L to 2536 ng/L; interquartile range, 35 ng/L to 154 ng/L). Distribution of the patients by hs-TnT subgroups was as follows: $<$ 3 ng/L, 134 (34%); $\geq$ 3 ng/L but $<$ 14 ng/L, 206 (52%), and $\geq$ 14 ng/L, 58 (15%).

ACS was diagnosed in 79 patients (20%). The criterion for diagnosis was evidence of coronary stenosis on coronary angiography in 71 patients (90%), a positive test for ischemia in 7 patients who refused to undergo coronary angiography, and a 30-day event (readmission for unstable angina and revascularization) in 1 patient who had been discharged after a negative exercise test. Table 1 shows the differences in the baseline characteristics between the subgroups with and without ACS.

The composite endpoint occurred in 59 patients (15%). There were no deaths. Acute myocardial infarction occurred in 6 patients (of these, 4 were related to the revascularization procedure), and revascularization was performed in 58 patients.

Univariable Analysis

NT-proBNP levels were higher in patients with a final diagnosis of ACS or the 30-day composite event than in the remaining patients median [interquartile range]: 98 [51-260] vs 59 [33-122] ng/L for the diagnosis of ACS ($P$=0.001); 101 [53-261] vs 62 [33-122] ng/L for the composite event ($P$=0.001).

Figure 1 shows the distribution of the study's endpoints according to NT-proBNP quartiles ($<$35, 35-66, 66-154, $\geq$154 ng/L). The frequency of both diagnosis of ACS (n=12, 12%; n=15, 16%; n=23, 23%; and n=29, 29%; $P$=0.01) and the composite event (n=6, 6%; n=13, 13%; n=16, 16%; and n=24, 24%; $P$=0.004) progressively increased with increasing NT-proBNP quartiles.

Elevated NT-proBNP levels ($>$ 125 ng/L) were found in 110 patients (28%). NT-proBNP elevation was associated with a diagnosis of ACS (28% vs 17%; RR=2.0; 95%CI, 1.2 to 3.3; $P$=0.02) and with the composite event (24% vs 12%; RR=2.4; 95% CI, 1.4 to 4.2; $P$=0.004) (Fig. 2).

Table 3 shows the agreement/disagreement between NT-proBNP $>$ 125 ng/L and hs-TnT $>$ 14 ng/L for the diagnosis of ACS and the composite event. The sensitivity, specificity and positive and negative predictive values (with 95%CI) of NT-proBNP for the 2 endpoints, respectively, were as follows: sensitivity: 39% (29% to 50%) and 44% (32% to 57%); specificity: 75% (70% to 80%) and 75% (70% to 80%); positive predictive value: 28% (21% to 37%) and 24% (17% to 33%); negative predictive value: 83% (79% to 87%) and 89% (84% to 92%). The corresponding values for hs-TnT $>$ 14 ng/L

| Table 2 |

Comparison of Population Characteristics Between Patients Included in the N-terminal Pro-brain Natriuretic Peptide Substudy and Those not Included due to the Lack of a Blood Sample for N-terminal Pro-brain Natriuretic Peptide Determination

<table>
<thead>
<tr>
<th>Without NT-proBNP (n=48)</th>
<th>With NT-proBNP (n=398)</th>
<th>P</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age, years</td>
<td>59±12</td>
<td>60±12</td>
</tr>
<tr>
<td>Men</td>
<td>27 (56)</td>
<td>235 (59)</td>
</tr>
<tr>
<td>Exercise-related chest pain</td>
<td>20 (42)</td>
<td>124 (31)</td>
</tr>
<tr>
<td>$\geq$2 episodes in the last 24 h</td>
<td>21 (44)</td>
<td>112 (33)</td>
</tr>
<tr>
<td>Smoking</td>
<td>7 (15)</td>
<td>104 (26)</td>
</tr>
<tr>
<td>Hypertension</td>
<td>28 (58)</td>
<td>184 (46)</td>
</tr>
<tr>
<td>Hypercholesterolemia</td>
<td>21 (44)</td>
<td>184 (46)</td>
</tr>
<tr>
<td>Diabetes</td>
<td>10 (21)</td>
<td>79 (20)</td>
</tr>
<tr>
<td>Family history</td>
<td>2 (4)</td>
<td>59 (15)</td>
</tr>
<tr>
<td>Peripheral artery disease</td>
<td>1 (2.1)</td>
<td>5 (1.3)</td>
</tr>
<tr>
<td>History of stroke</td>
<td>3 (6.3)</td>
<td>10 (2.5)</td>
</tr>
<tr>
<td>Prior antplatelet therapy</td>
<td>7 (15)</td>
<td>82 (21)</td>
</tr>
<tr>
<td>Prior statin therapy</td>
<td>14 (29)</td>
<td>115 (29)</td>
</tr>
<tr>
<td>Prior beta-blocker therapy</td>
<td>6 (13)</td>
<td>44 (11)</td>
</tr>
<tr>
<td>Systolic blood pressure on admission, mmHg</td>
<td>147±25</td>
<td>144±24</td>
</tr>
<tr>
<td>Diastolic blood pressure on admission, mmHg</td>
<td>80±13</td>
<td>80±13</td>
</tr>
<tr>
<td>Heart rate on admission, bpm</td>
<td>75±14</td>
<td>76±15</td>
</tr>
<tr>
<td>Ischemia on ECG (ST-segment depression ST$&gt;$0.5 mm/negative T wave $&gt;$2 mm)</td>
<td>3 (6)</td>
<td>55 (14)</td>
</tr>
<tr>
<td>Baseline creatinine, mg/dL</td>
<td>0.9±0.2</td>
<td>0.9±0.2</td>
</tr>
</tbody>
</table>

EKG, electrocardiogram; NT-proBNP, N-terminal pro-brain natriuretic peptide.

Values are expressed as no. (%) or mean±standard deviation.
Consequently, and Moreover, were 536 brain of the diagnosis natriuretic peptide levels ranged from 85% to 41%. This range includes values of 35-66 ng/L (upper quartile), 66-154 ng/L (median), and >154 ng/L (upper quartile). The NT-proBNP levels were associated with an increased risk of cardiovascular events, and the highest risk was found for NT-proBNP levels >154 ng/L (OR=3.2; 95% CI, 1.4 to 7.1; P=.048; NT-proBNP ≥ 14 ng/L vs <3 ng/L; OR=5.4; 95% CI, 2.1 to 13.8; P=.0001) and with the composite event (NT-proBNP ≥ 3 but <14 ng/L vs <3 ng/L; OR=5.6; 95% CI, 1.8 to 16.9; P=.002; NT-proBNP ≥ 14 ng/L vs <3 ng/L; OR=9.0; 95% CI, 2.7 to 30.4; P=.0001). However, NT-proBNP lacked predictive value (P=.3 for both endpoints). No significant differences were found in the C statistic of the models with and without NT-proBNP for diagnosis of ACS (0.805 and 0.804) or for the composite event (0.836 and 0.842).

**DISCUSSION**

The results of the present study show that, in patients presenting to the emergency department for chest pain without myocardial injury, or with only minimal damage, not detected by conventional troponin assays, hs-TnT provides information on diagnosis and prognosis and can therefore help in decision making. In contrast, NT-proBNP does not add to the information provided by hs-TnT and should not be routinely used.

**N-terminal Pro-brain Natriuretic Peptide and Chest Pain**

Myocardial ischemia provokes changes in the ventricular contractility and relaxation, which releases natriuretic peptides. Moreover, ischemia per se also facilitates the release of these substances. Consequently, there is a rational basis for considering that natriuretic peptides might be of value in risk stratification in ACS in addition to their value in heart failure.

Studies performed in the entire spectrum of ACS, including those occurring in patients with normal troponin levels, have shown that elevated natriuretic peptide levels were associated with an increased risk of cardiovascular events. More, in some of these studies, these substances provided additional prognostic value to that provided by troponin. Specifically, in patients with chest pain and normal troponin levels, evaluated in chest pain units, NT-proBNP elevations increased the 1-year risk of death or myocardial infarction. Low NT-proBNP levels in patients with chest pain and normal troponin levels could be used to identify low-risk patients who are candidates for discharge from the emergency service. Likewise, in primary prevention, natriuretic peptide elevation allowed identification of both silent heart disease and estimation of the 10-year risk of cardiovascular events independently of traditional risk factors and other biomarkers.

In the present study, however, NT-proBNP was only marginally useful in the evaluation of chest pain or uncertain etiology when hs-TnT was also employed. This result could be explained by several factors: a) the greater sensitivity of the reagent used in the Elecsys® hs-TnT assay in detecting myocardial injury, which is superior to the sensitivity of that used in other studies; b) in the PITAGORAS study, clinical data and risk factors were carefully gathered, allowing rigorous adjustment to the multivariable model. In particular, in the clinical history, the association between chest pain during exercise and recurrent pain was recorded, an association that previous studies have shown to be strongly associated with diagnosis of ACS and prognosis in patients with the same characteristics as those enrolled in the PITAGORAS study; c) the most consistent association found for natriuretic peptides in previous studies has been with major cardiovascular events, particularly mortality, and in the long term. Due to its

**Figure 1.** Frequency of the diagnosis of acute coronary syndrome (upper graph) and of the 30-day composite event (lower graph) according to N-terminal pro-brain natriuretic peptide quartiles. NT-proBNP, N-terminal pro-brain natriuretic peptide.

**Figure 2.** Relative risk of N-terminal pro-brain natriuretic peptide >125 ng/L for the diagnosis of acute coronary syndrome and the 30-day composite event. 95% CI, 95% confidence interval; NT-proBNP, N-terminal pro-brain natriuretic peptide; RR, relative risk.

**Tables 4 and 5** show the multivariable models for the endpoints of the study, including clinical variables, ECG data, hs-TnT, and NT-proBNP. The variables related to a diagnosis of ACS or the composite event were male sex, association of chest pain with exercise, 2 or more episodes of chest pain in the last 24 h, diabetes, prior statin therapy, and a finding of ischemia on the el ECG.

A strong association was found between hs-TnT and diagnosis of ACS (hs-TnT ≥ 3 but <14 ng/L vs <3 ng/L; OR=3.2; 95% CI, 1.4 to 7.1; P=.048; hs-TnT ≥ 14 ng/L vs <3 ng/L; OR=5.4; 95% CI, 2.1 to 13.8; P=.0001) and with the composite event (hs-TnT ≥ 3 but <14 ng/L vs <3 ng/L; OR=5.6; 95% CI, 1.8 to 16.9; P=.002; hs-TnT ≥ 14 ng/L vs <3 ng/L; OR=9.0; 95% CI, 2.7 to 30.4; P=.0001). However, NT-proBNP lacked predictive value (P=.3 for both endpoints). No significant differences were found in the C statistic of the models with and without NT-proBNP for diagnosis of ACS (0.805 and 0.804) or for the composite event (0.836 and 0.842).

**Multivariable Analysis**

The results of the present study show that, in patients presenting to the emergency department for chest pain without myocardial injury, or with only minimal damage, not detected by conventional troponin assays, hs-TnT provides information on diagnosis and prognosis and can therefore help in decision making. In contrast, NT-proBNP does not add to the information provided by hs-TnT and should not be routinely used.

**N-terminal Pro-brain Natriuretic Peptide and Chest Pain**

Myocardial ischemia provokes changes in the ventricular contractility and relaxation, which releases natriuretic peptides. Moreover, ischemia per se also facilitates the release of these substances. Consequently, there is a rational basis for considering that natriuretic peptides might be of value in risk stratification in ACS in addition to their value in heart failure.

Studies performed in the entire spectrum of ACS, including those occurring in patients with normal troponin levels, have shown that elevated natriuretic peptide levels were associated with an increased risk of cardiovascular events. More, in some of these studies, these substances provided additional prognostic value to that provided by troponin. Specifically, in patients with chest pain and normal troponin levels, evaluated in chest pain units, NT-proBNP elevations increased the 1-year risk of death or myocardial infarction. Low NT-proBNP levels in patients with chest pain and normal troponin levels could be used to identify low-risk patients who are candidates for discharge from the emergency service. Likewise, in primary prevention, natriuretic peptide elevation allowed identification of both silent heart disease and estimation of the 10-year risk of cardiovascular events independently of traditional risk factors and other biomarkers.

In the present study, however, NT-proBNP was only marginally useful in the evaluation of chest pain or uncertain etiology when hs-TnT was also employed. This result could be explained by several factors: a) the greater sensitivity of the reagent used in the Elecsys® hs-TnT assay in detecting myocardial injury, which is superior to the sensitivity of that used in other studies; b) in the PITAGORAS study, clinical data and risk factors were carefully gathered, allowing rigorous adjustment to the multivariable model. In particular, in the clinical history, the association between chest pain during exercise and recurrent pain was recorded, an association that previous studies have shown to be strongly associated with diagnosis of ACS and prognosis in patients with the same characteristics as those enrolled in the PITAGORAS study; c) the most consistent association found for natriuretic peptides in previous studies has been with major cardiovascular events, particularly mortality, and in the long term. Due to its
Table 3
Number of Patients With and Without Elevation of High-sensitivity Troponin T and N-terminal Pro-brain Natriuretic Peptide in the Subgroups With and Without a Diagnosis of Acute Coronary Syndrome and With and Without Events

<table>
<thead>
<tr>
<th>NT-proBNP, ng/L</th>
<th>With ACS (n=79)</th>
<th>Without ACS (n=319)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Hs-TnT&lt;14 ng/L</td>
<td>Hs-TnT≥14 ng/L</td>
</tr>
<tr>
<td>&lt;125</td>
<td>40 (73)</td>
<td>8 (33)</td>
</tr>
<tr>
<td>&gt;125</td>
<td>15 (27)</td>
<td>16 (67)</td>
</tr>
</tbody>
</table>

With events (n=59) Without events (n=139)

| <125            | 27 (69)        | 6 (30)              | 238 (79)       | 17 (45)             |
| >125            | 12 (31)        | 14 (70)             | 63 (21)        | 21 (55)             |

ACS, acute coronary syndrome; Hs-TnT, high-sensitivity troponin T; NT-proBNP, N-terminal pro-brain natriuretic peptide.
The percentages refer to those within each hs-TnT category.

Table 4
Multivariable Model with Clinical Variables N-terminal Pro-brain Natriuretic Peptide and High-sensitivity Troponin T for the Diagnosis of Acute Coronary Syndrome

<table>
<thead>
<tr>
<th>Variable</th>
<th>OR (95%CI)</th>
<th>P</th>
</tr>
</thead>
<tbody>
<tr>
<td>Male</td>
<td>2.0 (1.1-3.8)</td>
<td>.03</td>
</tr>
<tr>
<td>Association with exercise</td>
<td>3.4 (1.9-6.1)</td>
<td>.0001</td>
</tr>
<tr>
<td>Diabetes</td>
<td>2.5 (1.3-4.8)</td>
<td>.006</td>
</tr>
<tr>
<td>Ischemia on ECG</td>
<td>5.1 (2.5-10.3)</td>
<td>.001</td>
</tr>
<tr>
<td>Hs-TnT</td>
<td></td>
<td></td>
</tr>
<tr>
<td>≥3 ng/L but &lt;14 ng/L vs &lt;3 ng/L</td>
<td>3.2 (1.4-7.1)</td>
<td>.004</td>
</tr>
<tr>
<td>≥14 ng/L vs &lt;3 ng/L</td>
<td>5.4 (2.1-13.8)</td>
<td>.0001</td>
</tr>
<tr>
<td>NT-proBNP</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Quartiles</td>
<td>.3</td>
<td></td>
</tr>
</tbody>
</table>

95%CI, 95% confidence interval; ECG, electrocardiogram; hStnT, high-sensitivity troponin T; NT-proBNP, N-terminal pro-brain natriuretic peptide; OR, odds ratio.

design, the PIGAGORAS study included low-risk patients in the population with normal troponin levels, who are those without a prior history of ischemic heart disease. Thus, the events registered were mainly revascularizations prompted by the results of noninvasive tests and coronary angiography. However, the follow-up period was only 30 days. Nevertheless, when decisions are taken in the emergency department, identifying the patients in this population who could require a revascularization procedure in the short term is a priority, even though the benefits of revascularization in some low-risk patients might be questionable24; d) in ACS, the peak NT-proBNP value appears between 16 h and 24 h after arrival at the emergency department25; in the PIGAGORAS study, this determination was made between 6 h and 8 h after arrival at the emergency department. Determination at 24 h might have increased the predictive value; and e) the sample size of the study may have been insufficient, although the number of patients included was sufficient to demonstrate the predictive value of hs-TnT.

High-sensitivity Troponin T

The introduction of hs-TnT assays has modified the evaluation of patients with chest pain because elevations occur earlier in hs-TnT than in conventional troponins; in addition, hs-TnT can identify patients with myocardial damage that was previously undetected by conventional troponin assays26-29. Nevertheless, the PIGAGORAS study showed that the clinical history and ECG are essential in the evaluation of patients without myocardial injury or with minimal damage. The higher the hs-TnT levels, the greater the probability of a diagnosis of ACS and the risk of events, although the most important datum was the high negative predictive value of the absence of detectable hs-TnT levels in 2 serial determinations. The results of the present substudy suggest that NT-proBNP does not provide significant additional information in this context and, in view of cost-effectiveness considerations, should not be routinely determined when hs-TnT is used.

Limitations

A total of 48 patients in the PIGAGORAS study were not included in the present substudy of NT-proBNP due to lack of a blood sample. Nevertheless, no relevant differences were found in the characteristics of patients who were not included.

CONCLUSIONS

In low-risk patients with chest pain of uncertain etiology, such as those included in the PIGAGORAS study, who were evaluated with hs-TnT, the use of NT-proBNP provides no additional information to diagnosis or estimation of short-term prognosis. These conclusions should not be extrapolated to patients at higher risk or to evaluation of major cardiovascular events, such as mortality or myocardial infarction, in the long term.

FUNDING

An unrestricted grant from Roche Diagnostics (Basil, Switzerland). Instituto de Salud Carlos III (FEDER), Red HERACLES
(Drs. Sanchis and Bosch) and Red RECAVA (Drs. Sánchez, Hernández and Barrabés).

CONFLICTS OF INTEREST

None declared.

APPENDIX. LIST OF PARTICIPATING HOSPITALS AND THEIR INVESTIGATORS

Hospital Clínico Universitario, Valencia: Juan Sanchis, Arturo Carratalà, Lidia Abellán, Mauricio Pellicer and Cristina Gómez-Monsolíu; Hospital Universitari Vall de Hebrón, Barcelona: Jose A. Barrabés, Albert Alonso and Luzma Cruz; Hospital Universitari Joan XXIII, Tarragona: Alfredo Bardaji and Angés Vilanova; Hospital Gregorio Marañón, Madrid: Pedro L. Sánchez, Mercedes Garcia and Carolina Puerta; Hospital Meixoeiro, Vigo: Fran Calvo and Carmen Farreirós; Hospital Clinic, Barcelona: Xavier Bosch, Jose L. Bedini and Bernat Nadal; Hospital Josep Trueta, Girona: Pablo Loma, Manel Ramírez, Marina Fontant and Francisco Campelo Parada; Hospital Clínico Universitario, Valladolid: Carolina Hernández, Alberto San Román, Encarna Lago and Innaculada Vidriales; Hospital Virgen de la Arrixaca, Murcia: Francisco Marín, Ana Romero and Pedro Martínez; Hospital General de Asturias: Pablo Avanzas and Francisco Álvarez; Hospital Germans Trias i Pujol, Badalona: Silvia Serrano and Amparo Galán.

REFERENCES